Effort, Revenue, and Cost Sharing Mechanisms for Collaborative New Product Development

By Sreekumar R. Bhaskaran, Vish V. Krishnan. Management Sciences, 2009

441 citations recorded by the source corpus.

Subfields: Finance, Management Information Systems, Management of Technology and Innovation

View Paper: https://www.semanticscholar.org/paper/7e59bfc8e46217d464ff0e1ec9b79fc4c6cbc2db

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Finance

In Management Information Systems

In Management of Technology and Innovation

Citations in the corpus

Vertical Integration under Competition: Forward, Backward, or No Integration? (2012, background): “While a number of studies including ours treat quality improvement as a fixed cost investment (e.g., Bhaskaran and Krishnan 2009, Bonanno 1986, Demirhan et al. 2007, Kaya and €Ozer 2009), there are others assuming quality improvement accompanies an increase in marginal production cost.”
The Impact of Contracts and Competition on Upstream Innovation in a Supply Chain (2015, background): “Bhaskaran and Krishnan (2009) examine revenue-sharing, investment (cost) sharing and innovation (effort) sharing contracts in collaborating new product development, and show that for projects with substantial timing uncertainty, investment sharing works better, whereas for projects with quality…”
Cost-sharing mechanism for product quality improvement in a supply chain under competition (2019, background): “In recent years, there has been a wide variety of research papers that apply noncooperative game (Choi, 1991; Choi, 1996 etc) as well as cooperative bargaining (Kohli and Park, 1989; Bhaskaran and Krishnan, 2009) framework to the field of supply chain management.”
Supply chain analysis under green sensitive consumer demand and cost sharing contract (2015, background): “Bhaskaran and Krishnan (2009) discuss another case of cost sharing between a large pharmaceutical company and its lab partner, where the large pharmaceutical company shares the investment cost with its lab partner for developing and commercializing innovative class of diabetes drugs.”